Gilead Sciences (GILD) Gains from Investment Securities (2009 - 2026)

Gilead Sciences (GILD) has reported Gains from Investment Securities for 18 consecutive years, with $17.0 million the latest figure, recorded in Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $17.0 million, up 103.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $441.0 million (up 192.07% YoY), and the FY2025 annual result was -$2.0 million, up 96.55% from the prior year.
• Gains from Investment Securities was $17.0 million for Q1 2026 at Gilead Sciences, up from -$11.0 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $661.0 million in Q3 2024 and troughed at -$640.0 million in Q3 2022.
• Average Gains from Investment Securities over 5 years is -$16.1 million, with a median of -$19.5 million recorded in 2025.
• Year-over-year, Gains from Investment Securities surged 824.59% in 2023 and plunged 8420.0% in 2025.
• Over 5 years, Gains from Investment Securities stood at -$61.0 million in 2022, then soared by 824.59% to $442.0 million in 2023, then sank by 215.61% to -$511.0 million in 2024, then surged by 97.85% to -$11.0 million in 2025, then surged by 254.55% to $17.0 million in 2026.
• Per Business Quant data, the three most recent Gains from Investment Securities figures were $17.0 million in Q1 2026, -$11.0 million in Q4 2025, and -$28.0 million in Q3 2025.